Volume 20, Issue 2

Multimodal profiling of peripheral blood identifies proliferating circulating effector CD4+ T cells as predictors for response to integrin α4β7-blocking therapy in inflammatory bowel disease Horn V, Cancino CA, Steinheuer LM, et al. Gastroenterology 2025;168:327–43.

Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysis Gros B, Blackwell J, Segal J, et al. Lancet Gastroenterol Hepatol 2024;9:1030–40.

Jonas Halfvarsson is a familiar name to most colleagues and a leading expert in the global Inflammatory Bowel Disease (IBD) field. He is a professor of gastroenterology at Örebro University and a consultant gastroenterologist at Örebro University Hospital in Sweden.

Dear ECCO friends and family, welcome to this interesting discussion with Dr. Tian Hong Wu first author of the exciting paper “Natural History of Crohn’s Disease Leading to Intestinal Failure: A Longitudinal Cohort Study from 1973 to 2018”.